Pharma Chips Away at Discount Drugs While Battling HHS in Court

Major pharmaceutical companies continue cutting off for-profit pharmacies from drug discounts aimed at helping low-income patients even as they fight the HHS in courts across the country—a trend with no end in sight.

AbbVie Inc., Amgen Inc., and Bristol Myers Squibb are among the latest companies to limit the price cuts they offer through the government’s 340B program, which requires drugmakers to give discounts to providers serving vulnerable populations in exchange for their drugs participating in Medicaid and Medicare Part B.

Courts have handed down conflicting rulings over the government’s authority to force drugmakers to fork over these discounts, ...